Development of an automated immunoassay for advanced glycosylation end products in human serum

Chuai Yu Lin, Chuan Sern Chen, Ming Song Shieh, Chih Hsiung Wu, Horng Mo Lee

研究成果: 雜誌貢獻文章

2 引文 (Scopus)

摘要

Objective: Nonenzymatic reaction of protein and carbohydrate produce a series of brown fluorescent advanced glycosylation end products (AGEs). However, a convenient and rapid assay for serum AGEs level is currently unavailable. Methods: We raised AGEs-specific polyclonal antibodies, which were used to develop a fully automated, noncompetitive, homogeneous, light-scattering immunoassay for serum AGEs. Results: The assay requires a sample volume of 2 μL and takes a reaction time of 2 min. The coefficient of variation range from 1.8 to 6.1%, and the mean recovery rate was 98.6%. Comparative analysis shows moderate correlation with competitive ELISA (r = 0.8209, n = 52). The mean ± SD concentration of AGEs in young and in older healthy subjects were 4.6 ± 1.5 (n = 39) and 4.9 ± 1.4 (n = 40), respectively. The level of AGEs was significantly higher in serum from patients with type II DM 7.8 ± 4.8 (n = 89) than that from the normal subjects (p <0.05). Conclusions: The automatic immunoassay for AGEs is appropriate for clinical use.
原文英語
頁(從 - 到)189-195
頁數7
期刊Clinical Biochemistry
35
發行號3
DOIs
出版狀態已發佈 - 2002

指紋

Advanced Glycosylation End Products
Immunoassay
Assays
Serum
Light scattering
Carbohydrates
Recovery
Antibodies
Healthy Volunteers
Enzyme-Linked Immunosorbent Assay
Light
Proteins

ASJC Scopus subject areas

  • Clinical Biochemistry

引用此文

Development of an automated immunoassay for advanced glycosylation end products in human serum. / Lin, Chuai Yu; Chen, Chuan Sern; Shieh, Ming Song; Wu, Chih Hsiung; Lee, Horng Mo.

於: Clinical Biochemistry, 卷 35, 編號 3, 2002, p. 189-195.

研究成果: 雜誌貢獻文章

Lin, Chuai Yu ; Chen, Chuan Sern ; Shieh, Ming Song ; Wu, Chih Hsiung ; Lee, Horng Mo. / Development of an automated immunoassay for advanced glycosylation end products in human serum. 於: Clinical Biochemistry. 2002 ; 卷 35, 編號 3. 頁 189-195.
@article{9964cdc584164d6ca915f4f1f10b10ec,
title = "Development of an automated immunoassay for advanced glycosylation end products in human serum",
abstract = "Objective: Nonenzymatic reaction of protein and carbohydrate produce a series of brown fluorescent advanced glycosylation end products (AGEs). However, a convenient and rapid assay for serum AGEs level is currently unavailable. Methods: We raised AGEs-specific polyclonal antibodies, which were used to develop a fully automated, noncompetitive, homogeneous, light-scattering immunoassay for serum AGEs. Results: The assay requires a sample volume of 2 μL and takes a reaction time of 2 min. The coefficient of variation range from 1.8 to 6.1{\%}, and the mean recovery rate was 98.6{\%}. Comparative analysis shows moderate correlation with competitive ELISA (r = 0.8209, n = 52). The mean ± SD concentration of AGEs in young and in older healthy subjects were 4.6 ± 1.5 (n = 39) and 4.9 ± 1.4 (n = 40), respectively. The level of AGEs was significantly higher in serum from patients with type II DM 7.8 ± 4.8 (n = 89) than that from the normal subjects (p <0.05). Conclusions: The automatic immunoassay for AGEs is appropriate for clinical use.",
keywords = "Advanced glycosylation end products, Competitive ELISA, Diabetes mellitus, End stage renal diseases, Light-scattering immunoassay",
author = "Lin, {Chuai Yu} and Chen, {Chuan Sern} and Shieh, {Ming Song} and Wu, {Chih Hsiung} and Lee, {Horng Mo}",
year = "2002",
doi = "10.1016/S0009-9120(02)00302-8",
language = "English",
volume = "35",
pages = "189--195",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Development of an automated immunoassay for advanced glycosylation end products in human serum

AU - Lin, Chuai Yu

AU - Chen, Chuan Sern

AU - Shieh, Ming Song

AU - Wu, Chih Hsiung

AU - Lee, Horng Mo

PY - 2002

Y1 - 2002

N2 - Objective: Nonenzymatic reaction of protein and carbohydrate produce a series of brown fluorescent advanced glycosylation end products (AGEs). However, a convenient and rapid assay for serum AGEs level is currently unavailable. Methods: We raised AGEs-specific polyclonal antibodies, which were used to develop a fully automated, noncompetitive, homogeneous, light-scattering immunoassay for serum AGEs. Results: The assay requires a sample volume of 2 μL and takes a reaction time of 2 min. The coefficient of variation range from 1.8 to 6.1%, and the mean recovery rate was 98.6%. Comparative analysis shows moderate correlation with competitive ELISA (r = 0.8209, n = 52). The mean ± SD concentration of AGEs in young and in older healthy subjects were 4.6 ± 1.5 (n = 39) and 4.9 ± 1.4 (n = 40), respectively. The level of AGEs was significantly higher in serum from patients with type II DM 7.8 ± 4.8 (n = 89) than that from the normal subjects (p <0.05). Conclusions: The automatic immunoassay for AGEs is appropriate for clinical use.

AB - Objective: Nonenzymatic reaction of protein and carbohydrate produce a series of brown fluorescent advanced glycosylation end products (AGEs). However, a convenient and rapid assay for serum AGEs level is currently unavailable. Methods: We raised AGEs-specific polyclonal antibodies, which were used to develop a fully automated, noncompetitive, homogeneous, light-scattering immunoassay for serum AGEs. Results: The assay requires a sample volume of 2 μL and takes a reaction time of 2 min. The coefficient of variation range from 1.8 to 6.1%, and the mean recovery rate was 98.6%. Comparative analysis shows moderate correlation with competitive ELISA (r = 0.8209, n = 52). The mean ± SD concentration of AGEs in young and in older healthy subjects were 4.6 ± 1.5 (n = 39) and 4.9 ± 1.4 (n = 40), respectively. The level of AGEs was significantly higher in serum from patients with type II DM 7.8 ± 4.8 (n = 89) than that from the normal subjects (p <0.05). Conclusions: The automatic immunoassay for AGEs is appropriate for clinical use.

KW - Advanced glycosylation end products

KW - Competitive ELISA

KW - Diabetes mellitus

KW - End stage renal diseases

KW - Light-scattering immunoassay

UR - http://www.scopus.com/inward/record.url?scp=0036017350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036017350&partnerID=8YFLogxK

U2 - 10.1016/S0009-9120(02)00302-8

DO - 10.1016/S0009-9120(02)00302-8

M3 - Article

C2 - 12074826

AN - SCOPUS:0036017350

VL - 35

SP - 189

EP - 195

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 3

ER -